Clinical Trials · NCT05761431

A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

CompletedPhase 1Octreotide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Enrollment
56
Start date
Mar 2023
Locations
1 site, China
Primary endpoint
Incidence and severity of adverse events
View Octreotide compound reference